Stryker Co. (NYSE:SYK) Shares Bought by Banco de Sabadell S.A

Banco de Sabadell S.A increased its position in Stryker Co. (NYSE:SYK) by 1.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 5,261 shares of the medical technology company’s stock after acquiring an additional 66 shares during the quarter. Banco de Sabadell S.A’s holdings in Stryker were worth $1,897,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of SYK. Fox Run Management L.L.C. purchased a new stake in Stryker during the fourth quarter worth $660,000. KLP Kapitalforvaltning AS acquired a new position in shares of Stryker during the 4th quarter worth $41,749,000. Umpqua Bank boosted its position in shares of Stryker by 2.7% in the 4th quarter. Umpqua Bank now owns 5,516 shares of the medical technology company’s stock worth $2,001,000 after buying an additional 147 shares in the last quarter. American Century Companies Inc. grew its stake in Stryker by 11.4% in the 4th quarter. American Century Companies Inc. now owns 743,693 shares of the medical technology company’s stock valued at $267,767,000 after acquiring an additional 75,897 shares during the last quarter. Finally, Plancorp LLC increased its holdings in Stryker by 27.9% during the 4th quarter. Plancorp LLC now owns 941 shares of the medical technology company’s stock valued at $339,000 after acquiring an additional 205 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SYK. Citigroup reaffirmed a “buy” rating and issued a $450.00 price target on shares of Stryker in a report on Wednesday, February 26th. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, March 6th. Argus set a $450.00 target price on Stryker in a report on Monday, February 3rd. The Goldman Sachs Group set a $422.00 price target on Stryker in a report on Tuesday, March 4th. Finally, Canaccord Genuity Group increased their price objective on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $421.90.

Stryker Stock Down 0.8 %

Shares of SYK opened at $371.38 on Friday. The firm has a market cap of $141.71 billion, a PE ratio of 47.86, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company’s fifty day moving average is $384.28 and its two-hundred day moving average is $374.03. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the company earned $3.46 EPS. Analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Insider Activity at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.